Similar articles

• Pathophysiology of obesity-induced insulin resistance and type 2 diabetes mellitus.

  Tataranni PA. Tataranni PA. Eur Rev Med Pharmacol Sci. 2002 Mar-Jun;6(2-3):27-32. Eur Rev Med Pharmacol Sci. 2002. PMID: 12708607 Review. No abstract available.
• Vascular dysfunction: a Janus face of visfatin in diabetes?

  Teoh H, Lovren F, Verma S. Teoh H, et al. Metabolism. 2007 Apr;56(4):459-61. doi: 10.1016/j.metabol.2006.12.002. Metabolism. 2007. PMID: 17379000 No abstract available.
• The metabolic syndrome and type 2 diabetes: role of the adipocyte.

  McPherson R, Jones PH. McPherson R, et al. Curr Opin Lipidol. 2003 Dec;14(6):549-53. doi: 10.1097/00041433-200312000-00001. Curr Opin Lipidol. 2003. PMID: 14624130 Review. No abstract available.
• Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.

  Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, Bárány P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P. Axelsson J, et al. Am J Kidney Dis. 2007 Feb;49(2):237-44. doi: 10.1053/j.ajkd.2006.11.021. Am J Kidney Dis. 2007. PMID: 17261426
• Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.

  Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, Meysamie A. Esteghamati A, et al. Diabetes Res Clin Pract. 2011 Feb;91(2):154-8. doi: 10.1016/j.diabres.2010.11.003. Epub 2010 Nov 30. Diabetes Res Clin Pract. 2011. PMID: 21122936